Optimizing Tebra Prior Authorization for Rheumatology Practices

Klivira streamlines **Tebra prior authorization for rheumatology** practices, automating the complex workflows associated with high-cost biologics and infusion therapies.

Rheumatology practices face significant administrative overhead managing prior authorizations for biologics, JAK inhibitors, and infusion therapies. For independent practices utilizing Tebra, efficient PA management is crucial for revenue cycle integrity and timely patient care. Klivira integrates with Tebra to transform this process, ensuring compliance with payer requirements and reducing manual effort.

Tebra's Role in Rheumatology Practice Management

Tebra, formerly Kareo, provides an integrated platform designed for the operational needs of small and independent practices, including rheumatology. While Tebra offers robust EHR and RCM functionalities, the inherent complexity of rheumatology prior authorizations, particularly for high-cost biologics, often necessitates significant manual intervention within these settings.

The Unique Prior Authorization Burden in Rheumatology

Rheumatology is among the highest-PA-burden specialties due to the chronic nature of diseases like RA, PsA, and AS, and the necessity of advanced biologic and targeted therapies. Categories such as TNF-alpha inhibitors, non-TNF biologics, JAK inhibitors, and infusion therapies consistently trigger prior authorization requirements, often demanding periodic re-authorization.

Critical Documentation for Rheumatology Prior Authorizations

Diagnosis documentation with specific ICD-10 codes and disease criteria (e.g., 2010 ACR/EULAR for RA).
Disease activity assessment scores (e.g., DAS28, CDAI, PASI) to justify treatment necessity.
Documentation of prior conventional DMARD trials (e.g., methotrexate) or contraindications.
Adherence to payer-specific step therapy protocols, including biosimilar substitution mandates.
Completion of required pre-initiation screenings, such as TB and hepatitis B/C.

Klivira's Integration with Tebra for Rheumatology Workflows

Klivira integrates with Tebra via its robust API, allowing for seamless data exchange and automation within the rheumatology workflow. This integration enables Klivira to launch from relevant clinical contexts, such as medication order entry or treatment plan updates, to initiate prior authorization requests. Our platform intelligently extracts necessary clinical data from Tebra's EHR to pre-populate X12 278 transactions and payer portal submissions.

Klivira's Specialized Capabilities for Rheumatology Prior Authorization

ACR-guideline-aware policy logic for precise step therapy sequencing per indication.
Automated biosimilar substitution routing that accounts for per-payer mandates.
Proactive periodic re-authorization workflows for chronic treatments, ensuring continuous coverage.
Intelligent routing for medical vs. pharmacy benefit claims based on administration mode and payer policy.
Support for specialty-specific nuances like weight-based dosing and pediatric guideline criteria where applicable.

Overcoming Common Rheumatology PA Denials

Common denial reasons in rheumatology PAs include incomplete step therapy documentation, failure to attempt required biosimilars, and missing disease activity scores. Klivira's intelligent policy engine and automated data validation proactively address these issues by ensuring all required clinical criteria are met and accurately documented before submission, significantly reducing denial rates for Tebra users.

Frequently asked questions

How does Klivira handle the step therapy requirements for biologics in Tebra?

Klivira's platform incorporates ACR-guideline-aware logic to guide step therapy sequencing. It analyzes patient history within Tebra and payer-specific policies to ensure the correct conventional DMARDs or biosimilars have been trialed and documented, preventing denials related to non-compliance with step therapy protocols.

Can Klivira manage re-authorizations for chronic rheumatology treatments?

Yes, Klivira supports periodic re-authorization workflows for chronic biologic treatments. Our system tracks approval expiry dates and prompts for necessary continuous response documentation from Tebra, automating the re-submission process to maintain uninterrupted patient access to therapy.

How does Klivira integrate with Tebra's EHR specifically for rheumatology?

Klivira integrates via the Tebra API, allowing it to pull relevant clinical data such as diagnoses, lab results, medication history, and disease activity scores directly from the patient chart. This data is then used to pre-populate prior authorization forms (X12 278) and payer portal submissions, minimizing manual data entry for rheumatology staff.

Does Klivira address the medical vs. pharmacy benefit split for rheumatology drugs?

Yes, Klivira's system is designed to intelligently route prior authorizations based on whether the drug falls under the medical or pharmacy benefit. This is particularly critical in rheumatology where the same agent might be self-administered (pharmacy benefit) or provider-administered (medical benefit), with distinct PA pathways.

What specific rheumatology order types does Klivira support within Tebra?

Klivira supports prior authorization for a broad range of rheumatology-related orders, including specialty medications (biologics, JAK inhibitors), infusion therapies, and advanced imaging. The system is designed to launch and gather context directly from medication orders or referral orders placed within Tebra.